Panbela Therapeutics, Inc. (PBLA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4850 |
| Open | 0.4704 |
| Bid | 0.4540 x 1100 |
| Ask | 0.4411 x 2200 |
| Day's Range | 0.4315 - 0.4905 |
| 52 Week Range | 0.4100 - 87.6000 |
| Volume | |
| Avg. Volume | 1,917,892 |
| Market Cap | 541,493 |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6950 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 265.00 |
- GlobeNewswire
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for patent JP 7232845 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. This patent, developed in collaboration with Syngene International Ltd., an integrate
- Simply Wall St.
When Will Panbela Therapeutics, Inc. (NASDAQ:PBLA) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Panbela Therapeutics...
- GlobeNewswire
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2022 and early 2023 Highlights: Significant progress was made on the conduct of the
